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Liver Transplantation for 
the Budd-Chiari Syndrome 
GLENN HALFF, M.D., SATORU TODO, M.D., ANDREAS G. TZAKIS, M.D., 
ROBERT D. GORDON, M.D., and THOMAS E. STARZL, M.D., PH.D. 
A retrospective study was performed that analyzed 23 patients 
who had an orthotopic liver transplantation for the Budd-Chiari 
syndrome with end-stage liver disease. Patient follow-up was as 
long as 14 years. The technical considerations relevant to the 
Budd-Chiari syndrome were discussed. There have been no se-
rious complications of postoperative anticoagulation. Three pa-
tients, all of whom died, had recurrence of the Budd-Chiari syn-
drome. No other patient has had evidence of recurrent Budd-
Chiari syndrome on postoperative liver biopsies. One-, 3-, and 
5-year actuarial survival was 68.8%, 44.7%, and 44.7%, respec-
tively. It was concluded that orthotopic liver transplantation is 
the most effective treatment for patients with the Budd-Chiari 
syndrome and end-stage liver disease. 
T HE BUDD-CHIARI SYNDROME is a poorly defined spectrum of disease ranging from a veno occlusive 
disorder with small vessel occlusion to thrombosis 
of the major hepatic veins and/or inferior vena cava, A 
wide variety of underlying disorders and risk factors such 
as paroxysmal nocturnal hemoglobinuria (PNH), poly-
cythemia vera and other myeloproliferative diseases, tu-
mors, amoebic abscesses, congenital venal caval webs, oral 
contraceptives, and pregnancy have been reported to cause 
the syndrome, although most cases of the syndrome have 
been attributed to cryptogenic causes. I,2 More recently 
antithrombin III deficiencies, lupus anticoagulants, and 
occult myeloproliferative diseases have been suggested to 
comprise a part of the cryptogenic category.3-5 Attempts 
at treatment have included anticoagulation, thrombolysis, 
portasystemic shunts, and liver transplantation. Although 
liver transplantation removes the cirrhotic liver disease, 
it may not cure the underlying thrombotic disorder. Re-
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currence of Budd-Chiari lesions in a transplanted liver 
has been previously described.6 In an additional report of 
17 patients from Cambridge who had liver transplants for 
Budd-Chiari, only one patient who was on anticoagulation 
therapy had a late death that may have been related to 
the underlying thrombotic disorder.7 We have described 
another large group of patients who have had liver trans-
plants for end-stage liver disease secondary to the Budd-
Chiari syndrome to discuss the long-term prognosis, to 
report the results of postoperative anticoagulation therapy, 
and to describe the technical problems associated with 
this disease. 
Materials and Methods 
Patients 
Twenty-three patients were transplanted for the Budd-
Chiari syndrome between 1974 and 1988. The transplants 
performed before 1981 were performed at the University 
of Colorado Medical Center in Denver, Colorado, and 
those after 1981 were performed at the Presbyterian-Uni-
versity Hospital in Pittsburgh, Pennsylvania. This repre-
sented 1.3% of patients undergoing liver transplantation 
during this time period. The diagnosis was confirmed by 
postresection pathologic examination in all patients. The 
ages at time of transplantation varied from 13 to 48 years, 
with a median age of 30 years. Three patients were male 
and 20 were female. 
The patients were diagnosed with the Budd-Chiari syn-
drome an average of 2.3 years (SO ± 2.7 years) before 
their transplants. The underlying etiologies (Table 1) in-
cluded paroxysmal nocturnal hemoglobinuria in 1, poly-
cythemia vera in 3, essential thrombocytosis in 1, and 
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TABLE I. Summar), oj Patient Data 
OLTx No. AtOp. OLTx Etiology Status Comments 
92 22 11/28/74 Polycythemia vera Alive No anticoagulation. 2 children 
post-transplant. liver biopsy 
1986 normal 
174 20 3/25/80 Oral contraceptive Died 6/81 multiple thrombotic 
lupus anticoagulant postoperative events without 
thrombocytosis anticoagulation, no 
thrombotic events for 1 year 
on anticoagulation; recurrent 
Budd-Chiari when 
anticoagulation stopped for a 
procedure 
179 21 6/5/80 Oral contraceptive Alive No anticoagulation, no 
thrombotic events 
181 16 8/23/80 Unknown Died 4/82 Retransplanted for chronic 
3/17 /82 rejection, no recurrent Budd-
3/25/82 Chiari, died of candidiasis 
270 28 12/11/82 Oral contraceptive Died 1/83 Aspergillus pneumonia 
371 31 3/18/84 Unknown Died 1/87 Died from recurrent Budd-
Chiari; one episode of 
subtherapeutic 
anticoagulation 
385 40 4/20/84 Unknown Alive Liver biopsy 4/86 normal 
511 22 4/4/85 Oral contraceptive Alive Hepatic artery thrombosis 9/85, 
subtherapeutic 
anticoagulation, not 
retransplanted 
624 35 10/9/85 Polycythemia vera; oral Died 12/85 Pseudomonas pneumonia 
contraceptive 
733 38 3/2/86 Polycythemia vera Died 3/86 Candidiasis 
735 36 3/4/86 Unknown Died 4/86 Cecal perforation 
736 13 3/4/86 Cysteamine Alive No anticoagulation, no 
thrombotic events 
919 40 10/12/86 Unknown Alive Liver biopsy 2/87, normal 
1151 30 7/4/87 Unknown Alive 
1230 35 9/13/87 Essential Died 11/87 Pseudomonas pneumonia 
thrombocytosis 
1247 25 9/25/87 Oral contraceptive Died 9/87 Intraoperative death from 
pulmonary emboli 
1281 29 10/31/87 PNH Died 11/87 OLTx #1: primary nonfunction 
11/1/87 OL Tx #2: thrombosed hepatic 
11/5/87 artery 
OLTx #3: thrombosed hepatic 
and portal vein, Aspergillus 
in thrombus artery 
1478 48 4/12/88 Unknown Alive 
1487 25 4/19/88 Oral contraceptive Alive 
1693 21 9/9/88 Oral contraceptive Alive 
1709 35 9/22/88 Unknown Alive OL Tx #1: primary nonfunction 
9/24/88 
1755 42 10/30/88 Unknown Alive 
1774 32 11/10/88 Lupus anticoagulant Alive 
OL Tx, orthotopic liver transplantation. PNH, paroxysmal nocturnal hemoglobinuria. 
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cysteamine administration for the treatment of cystinosis 
in I. Seven of the patients had a significant history of oral 
contraceptive use. Two of these patients had an anti-
thrombin III deficiency and two had a protein C defi-
ciency, but each of these had an accompanying deficiency 
of other coagulation factors that made a decrease in he-
patic synthetic function the likely cause. Two patients 
had associated lupus anticoagulants. The cause in the re-
maining nine (39%) patients was cryptogenic. 
The patient with PNH was diagnosed 10 years before 
symptoms of end-stage liver disease began. The patients 
with myeloproliferative disorders were diagnosed 6 years 
before liver disease became clinically significant in 1, dur-
ing the work-up for Budd-Chiari syndrome, which was 1 
year before operation, in 1, and 7 years after operation 
in 1 patient who had no known cause at the time of trans-
plantation. 
The Budd-Chiari syndrome was initially diagnosed by 
clinical presentation and a liver biopsy with or without a 
venogram in 74%, and only by a venogram in 26%. An 
ultrasound added diagnostic confirmation in 14 of 15 
(93%) of the patients in whom it was used. 
In more recent patients the venogram was not per-
formed unless there was a diagnostic question after liver 
biopsy and ultrasound had been performed. Nuclear 
magnetic resonance imaging has added additional con-
firmation in all eight patients it was used on during the 
last 2 years. 
Five of the patients had a history of previous portal 
caval shunts and four had had peritoneal venous shunts 
placed. Three patients had been treated unsuccessfully 
with anticoagulants and thrombolysis. Prior thrombotic 
events had occurred in 3 patients (a deep venous throm-
bosis in I, a pulmonary emboli in 2, 1 of whom required 
thoracotomy and embolectomy, and a sagittal sinus 
thrombosis in 1). The sagittal sinus thrombosis presented 
as a severe headache. 
Indications for orthotopic liver transplantation included 
end-stage liver disease with intractable ascites in 52%, re-
current variceal bleeds in 43%, encephalopathy in 47%, 
spontaneous bacterial peritonitis in 9%, and hepatorenal 
failure in 34%. One of the patients was intubated in the 
intensive care unit and was placed on vasopressors im-
mediately before transplantation. The decrease in syn-
thetic function of the liver was not as severe as that in 
many other causes of end-stage liver disease. The average 
prothrombin time was 14.9 seconds (SO ± 0.7), the av-
erage bilirubin was 4.3 mg/dL (SO ± 3.2), and the average 
albumin was 2.8 am/dL (SO ± 0.69). 
Technical Considerations 
At operation 30% of the patients were found to have 
dense adhesions between the liver and diaphragm sur-
rounding the suprahepatic inferior vena cava (IVC). Al-
most all of the patients had severe portal hypertension. 
The dissection was usually very difficult due to the large 
liver size and typically enlarged caudate lobe. The average 
liver volume on preoperative Cat scan was 2441 cc (SO 
± 752 cc). Portal bypass was usually instituted early in 
the operation before most of the liver dissection to de-
crease the blood loss related to the severe portal hyper-
tension. In some cases the connective tissue around the 
suprahepatic IVC was so dense that it could not be safely 
encircled to apply a clamp. In these cases the infrahepatic 
IVC was ligated and oversewn and the liver was then dis-
sected in a retrograde fashion up to the suprahepatic in-
ferior vena cava, as has been previously described, 8 with 
the remainder of the operation preceding in the standard 
fashion. 9 The suprahepatic vena caval cuff was fashioned 
in some cases by dissecting superiorly up to the right 
atrium. This was done through the diaphragm (Fig. 1). A 
thoracic extension was not necessary in any of the patients. 
The average intraoperative blood loss was 21.8 units (SO 
± 17.6). 
Anticoagulation 
Most patients within the last 5 years were given dextran 
40 at 20 cc/hour beginning immediately after operation 
and continuing for five days. Twenty-five hundred units 
of subcutaneous heparin BIO was begun on postoperative 
day 1 if the prothrombin time was less than 18 seconds 
and there was no postoperative bleeding. When the pa-
tients' clinical courses were stable with no future plans 
for invasive procedures, the patients' were converted to 
Warfarin anticoagulation. This was done an average of 
4.6 days (SO ± 6.2) after operation. Two patients who 
had early deaths and were never put on Coumadin 
FIG. 1. Suprahepatic venal caval cuff construction by dissection through 
the diaphram. 
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(DuPont, Wilmington, DE) due to a coagulopathy were 
excluded from this calculation. When an invasive pro-
cedure such as a liver biopsy or operation was planned, 
the patients were converted to heparin anticoagulation 
with a partial thromboplastin time between 1.5 and 2 
times control, which was stopped shortly before the pro-
cedure and restarted 6 hours after the procedure if there 
seemed to be no significant bleeding. 
Results 
Pathologic Findings In the Native Liver 
Thrombosed main hepatic veins were found in the na-
tive liver pathologic specimens in 83% of the patients. 
Four (17%) also had nonocclusive thrombus in their lYe. 
One of these four livers had membranous webs in the 
retrohepatic IYC in addition to thrombosed hepatic veins 
and cirrhosis. Typical histologic findings were central lob-
ular congestion and necrosis with dilation of the sinusoids, 
obliteration of central veins, varying degrees of central-
to-central and central-to-portal bridging fibrosis, and or-
ganized thrombus in branches of the main hepatic veins. 
Recipient Survival 
Overall 16 of 23 (69.5%) of the patients survived the 
initial hospitalization, including all six operated on during 
1988. One-, 3-, and 5-year actuarial survival was 68.8%, 
44.7%, and 44.7%, respectively. This compared with 1-, 
3-, and 5-year survivals of 69%, 61 %, and 57.6%, respec-
tively, in the age-matched population of all transplanted 
patients in the Pittsburgh-Denver experience. This dif-
ference did not achieve statistical significance using the 
generalized Wilcoxin (Breslow) Method. The P value was 
0.50. Using this method, the patients transplanted within 
the last year were excluded from the calculation. Included 
were Colorado patients from the precyclosporine era in 
which I-year overall survival in adults was approxi-
mately 25%. 
Causes of Death 
Causes of early death included Pseudomonas, Candida, 
and Aspergillus pneumonias, sepsis from a cecal perfo-
ration secondary to an ileus despite colonoscopic de-
compression, an intraoperative death from a massive pul-
monary emboli and, in one patient, a thrombosed hepatic 
artery and portal vein. Late deaths were caused by systemic 
candidiasis after a retransplant for chronic rejection in 
one patient and recurrent Budd-Chiari in two patients. 
Disease Recurrence 
Recurrence of the Budd-Chiari Syndrome or postop-
erative thrombotic complications of the hepatic vessels 
occurred in three patients who were studied at autopsy. 
One patient suffered thrombosis of her hepatic artery and 
portal vein 1 week after operation. The thrombus in both 
grew aspergilli. This patient, with an underlying etiology 
of PNH, had thrombosed the hepatic artery in a previous 
graft four days after operation despite therapeutic levels 
of anticoagulation. In a second patient, the recurrent 
Budd-Chiari syndrome occurred acutely after Coumadin 
was held for a procedure without interim heparin therapy. 
On autopsy, more than 1 year after transplantation, the 
liver showed evidence of previous recurrent Budd-Chiari 
syndrome with fibrous occlusion of multiple central and 
sublobular hepatic veins, old thrombi in the hepatic artery 
and left renal vein, as well as recent thrombi in the portal 
vein, IVC, hepatic veins, and pulmonary artery. This pa-
tient had been started on Coumadin after transplantation 
after she had recurrent postoperative mesenteric throm-
boses with intestinal infarction, multiple pulmonary em-
boli, and thrombosis of the superior vena cava. She had 
remained asymptomatic on Coumadin for more than 1 
year despite several subtherapeutic prothrombin times. 
An initial extensive evaluation did not show an etiology 
for her hypercoagulability and repeated evaluation just 
before stopping her Coumadin dosage for the procedure 
showed a thrombocytosis possibly related to a myeloid 
stem disease and a lupuslike inhibitor of the coagulation 
system. This patient has been previously reported.6 
The third patient, who died from a recurrent Budd-
Chiari syndrome, was therapeutically anticoagulated ex-
cept for one four-day period 4 months before she was 
admitted with a fever and elevated liver enzymes. After 
admission she had a rapid clinical deterioration. On au-
topsy she was found to have severe old and recent intra-
hepatic hepatic vein thrombosis. The other vessels were 
patent. She had a cryptogenic etiology for her Budd-Chiari 
syndrome. 
The patient who died of candidiasis after a retransplant 
for chronic rejection 1.5 years after her first transplant 
had no evidence of recurrent Budd-Chiari syndrome on 
pathologic exam of her first allograft. 
Biopsy of the liver has been performed in a number of 
the patients after operation. Patient 93 had a liver biopsy 
12 years after operation that showed no evidence of re-
currence of Budd-Chiari despite not being treated with 
anticoagulation. She was diagnosed with polycythemia 
vera 7 years after transplantation. Patient 385 had a liver 
biopsy 2 years after operation that showed no evidence 
of recurrent Budd-Chiari. No other patient has had evi-
dence of recurrent Budd-Chiari in a biopsy. However most 
of their biopsies were done within 1 month of trans plan-
tation. 
Anticoagulation and Thrombosis 
No patient has had a serious complication caused by 
anticoagulation. The patients' anticoagulation treatment 
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has been followed closely either in the liver transplantation 
clinic or by their local physicians. The prothrombin times 
have been steadily maintained between 18 and 20 seconds 
with occasional drops to 15 and peaks to 24 seconds. 
Postoperative thrombotic events occurred in the three 
patients previously mentioned and in two additional pa-
tients. One had a splenic vein thrombosis that led to var-
iceal bleeding and was successfully treated with a sple-
nectomy. This was the earliest patient with the longest 
follow-up, now 14.5 years. Her transplantation was on 
November 28, 1974.10 She was not treated with antico-
agulation medication. Another patient suffered throm-
bosis of her hepatic artery 5 months after operation. Her 
prothrombin time was 14 to 15 seconds at that time. She 
developed multiple hepatic abscesses and was treated with 
surgical drainage after refusing retransplantation. She is 
now doing well 4 years after the hepatic artery throm-
bosed. 
Discussion 
Budd-Chiari is a syndrome of decreased hepatic outflow 
caused by varying degrees of hepatic venous occlusion. It 
may present acutely with right upper quadrant pain, as-
cites, and hepatomegaly, or gradually over a period of 
months or years, with slowly increasing ascites and/or 
variceal bleeds. The liver becomes progressively more 
congested and the majority of untreated patients even-
tually die from the complications of end-stage liver dis-
ease. II In the study by Tavill et al., 12 the mortality rate in 
19 patients was 89%, with all 17 deaths occurring within 
3.5 years of symptom onset. 
Medical treatment with thrombolysis and/or antico-
agulation has been successful in a small number of pa-
tients. Warren et al. 13 reported successful treatment with 
streptokinase in one patient with 4 months of follow-up. 
Greenwoodl4 reported an initially successful outcome in 
one patient treated with urokinase who later rethrombosed 
and died of a variceal bleed 1.5 years later. Although there 
have been reports of successful thrombolytic therapy 
months after symptoms began,15 thrombolysis usually 
works better if used soon after thrombosis has occurred. 
This is not practical in most Budd-Chiari patients because 
they generally present with a long history of symptoms. 
In Parker's studyll only 20% of the patients presented 
with less than a I-month history of symptoms. Powell-
Jackson et al. 16 described streptokinase or heparin treat-
ment in five patients with a I-to-6 week history ofsymp-
toms. Treatment was successful in only one of the five 
patients and this patient was found to have cirrhosis on 
liver biopsy 10 years later. Her Budd-Chiari occurred sec-
ondary to trauma and she was treated with heparin. 
McDermott et al. 17 reported two patients with Budd-
Chiari secondary to oral contraceptives who gradually 
improved with only anticoagulant treatment. Millikan et 
al. 18 described one patient who experienced recanalization 
of his hepatic veins after only diuretic treatment. This 
patient initially only had partial hepatic vein occlusion. 
Surgical alternatives to treatment have included peri-
toneal venous shunts, portal-systemic shunts, and ortho-
topic liver transplantation. Peritoneal venous shunts have 
palliated the symptoms of massive ascites but have been 
unsuccessful in decreasing the mortality rate from the un-
derlying progressive liver disease. Cameronl9 documented 
two patients who developed histologic liver fibrosis after 
being treated with working Leveen shunts, as well as one 
patient who died of liver failure with a Leveen shunt. 
Some of these patients survived for several years. 
Surgical treatment with portal systemic shunts has been 
considered the treatment of choice in patients well enough 
to undergo surgery, although in some studies comparing 
medical and surgical treatment the groups were acknowl-
edged not to be comparable, with the sickest nonoperable 
patients receiving medical treatment only. McCarthy20 
reported an 86% mortality rate after a mean survival of 
6 months in 14 medically treated patients versus a 31 % 
mortality rate in a very mixed group of 16 surgically 
treated patients with another four of the surgically treated 
patients having ongoing hepatic disease. In Ahn's study21 
'Of 30 patients, the 2-year survival rate in the medically 
treated group was 9%, versus 54% in the surgically treated 
group. This did not achieve statistical significance due to 
the small numbers, but a subgroup of surgically treated 
patients in which the IVC obstruction was also treated 
did have a significantly better survival rate (77% at 2 years). 
The number of different surgical procedures to treat Budd-
Chiari has been reported to be as high as 2321 and the 
results reported from different institutions have varied 
greatly. Inferior vena caval webs are common in the Orient 
and can often be treated with different types of mem-
branotomy,22 but this form of Budd-Chiari is very un-
common in the United States and was not represented at 
all in our series. The most commonly used procedures in 
the United States are the side-to-side portacaval shunt 
and the mesocaval shunt, when the IVC and portal vein 
are patent, and the mesoatrial shunt when the IVC is 
stenosed or thrombosed, with a patent portal vein. The 
mesocaval shunt has often been used when the enlarged 
caudate lobe made portacaval exposure very difficult. 
The successful results with these surgical procedures 
range from 30% to 92%, with the majority having survival 
rates in the 60%-to-75% range. In Cameron's report l9 of 
12 patients operated on for Budd-Chiari, two of five pa-
tients with mesocaval shunts did well with some improve-
ment in sinusoidal congestion on postoperative biopsy. 
Of seven patients given mesoatrial shunts, three of seven 
were successful, but two of these three thrombosed and 
had to be redone. Of six patients who had portacaval 
shunts for Budd-Chiari reported in Miian,23 two of six 
died of liver failure and four are alive at 6, 25, 27, and 
29 months without encephalopathy. Ahn21 had estimated 
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1- and 2-year survival rates with surgical treatment for 
Budd-Chiari of 61 % and 54%. Vons24 reported nine pa-
tients with Budd-Chiari; seven were treated with a me-
socaval shunt and two with a portal-atrial shunt. One died 
and one was lost to follow-up, but the remaining seven 
are known to be alive without encephalopathy with a me-
dian follow-up of 23 months. The operative indications 
were ascites and right upper-quadrant pain. He reported 
that three of the patients had resolution of sinusoidal 
congestion on liver biopsy 1.5 to 2 years after operation. 
Mitchell et al. I compiled a report of 27 patients in the 
literature who had side-to-side portacaval shunts. Only 
30% survived and improved clinically for more than 1 
year. This group included the six patients in Orloff's re-
port, of whom five were alive after 8 months to 7 years 
without ascites or encephalopathy.25 Follow-up biopsy in 
this group showed resolution of sinusoidal congestion with 
persistence of mild-to-moderate fibrosis. In some patients 
operated on before fibrosis was present on histologic ex-
amination, or in whom the fibrosis was mild, the conges-
tion and sinusoidal dilatation resolved to a large degree 
on subsequent postshunt biopsies and the patients did 
well. In 1986 Orloff26 reported a total of 13 patients treated 
with portacaval shunts for the Budd-Chiari Syndrome. 
Ninety-two per cent were alive without ascites with follow-
up from 3 to 16 years. None of the patients had enceph-
alopathyand 10 of the 12 were reported to have had return 
of normal liver function. The degree of preoperative liver 
disease was not described. Millikan et al.,18 however, re-
ported on the status of a patient 6 years after portacaval 
shunt for Budd-Chiari who was doing well but developed 
fibrosis with nodular regeneration on biopsy. This raises 
the question of the long-term progression of liver disease 
in patients who have portosystemic shunts. Five of our 
23 (22%) recipients were treatment failures with this ap-
proach; their shunts were all widely patent. 
In patients with end-stage liver disease manifested by 
cirrhosis on biopsy and by clinical symptoms, the treat-
ment of choice, in our opinion, is orthotopic liver trans-
plantation. The first successful orthotopic liver transplan-
tation for Budd-Chiari was in 1974.10 This patient is still 
alive and well and has had two children since her trans-
plant. Campbell et al.7 described 17 patients treated with 
orthotopic liver transplantation for the Budd-Chiari syn-
drome. They emphasized the importance of postoperative 
anticoagulant treatment and reported 1- and 3-year sur-
vival rates of 88% in the group that was anticoagulated. 
Their overall I-year actuarial survival rate was 73%. Three 
additional patients died between 3 and 5 years after op-
eration, one from liver failure whose portal vein had 
thrombosed 6 months after operation, one from lym-
phoma, and one from chronic rejection. Their indications 
for transplantation included transient encephalopathy in 
three patients, progressive encephalopathy in one patient, 
and a progressive downhill course in the rest. 
In our own series the 1-, 3-, and 5-year actuarial survival 
rates were 68.8%, 44.7%, and 44.7%, respectively. This 
group of patients had many high risk problems, including 
previous failed shunt surgery, thrombosed portal veins, 
and severe portal hypertension. Most of the deaths have 
occurred during the initial hospitalization, most often 
from pneumonia and other forms of sepsis. There has 
been a trend of improvement with no deaths during the 
initial hospitalization in the six patients transplanted for 
Budd-Chiari during 1988. 
There was a second mortality rate peak during the first 
2 years after operation from thrombotic complications, 
but this was seen in the earlier years of the study and was 
at least partially due to anticoagulant management. 
The technical aspects of a liver transplantation for 
Budd-Chiari have sometimes differed from transplanta-
tion for other diseases. Dense adhesions around the su-
prahepatic IVC often make a retrograde hepatic dissection 
the safest method and have allowed the dissection to be 
done without extension of the operation into the chest in 
all patients. The development of veno-venous bypass in 
1983 had a major impact in this subgroup of transplant 
patients due to the severe portal hypertension that is usu-
ally found with Budd-Chiari. For this reason the veno-
venous bypass is usually instituted before the liver dis-
section is undertaken. 
Recurrence of the Budd-Chiari syndrome was seen in 
two resected liver allografts examined 2.8 and 1.2 years 
after transplant. Both of these patients had at least one 
documented period of subtherapeutic anticoagulant 
treatment. One other allograft in a patient adequately an-
ticoagulated was examined after 1.5 years and had no 
evidence of Budd-Chiari recurrence. In patient 93 the bi-
opsyat 12 years showed no sign ofBudd-Chiari recurrence 
despite no anticoagulant treatment. It is not possible to 
know if recurrent Budd-Chiari would have been prevented 
in those patients who developed recurrence if they had 
been anticoagulated adequately at all times or if the un-
derlying disease would have caused the problem anyway. 
It is clear that anticoagulant treatment was essential in 
some of the patients based on the experience of thrombotic 
episodes occurring with anticoagulant withdrawal, as well 
as with reported thrombotic episodes without anticoag-
ulation therapy that did not recur with anticoagulation. 
If the Budd-Chiari syndrome is caused by anti-thrombin-
III or protein C deficiency or by another protein made in 
the liver, then liver transplantation may be curative in 
this group of patients and they may not require postop-
erative anticoagulation. A patient with homozygous pro-
tein C deficiency who was cured with liver transplantation 
has been reported from Pittsburgh.27 
However, until a subgroup is well defined that does not 
require anticoagulation, all post-transplant Budd-Chiari 
patients should be therapeutically anticoagulated. We ex-
perienced no anticoagulant complications with close fol-
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low-up of all patients. Based on the Cambridge experience 
in which only 1 of 16 anticoagulated patients had a late 
thrombotic-related death and in our experience in which 
3 of 23 patients had recurrent Budd-Chiari syndrome, at 
least one of which was not adequately anticoagulated, it 
certainly seems that liver transplantation is indicated for 
the Budd-Chiari syndrome when associated end-stage liver 
disease is present. The underlying disease should be treated 
as much as is possible. 
In summary 23 patients in our experience who had 
liver transplantation for the Budd-Chiari syndrome were 
reviewed. Orthotopic liver transplantation for the Budd-
Chiari syndrome can be done with acceptable morbidity 
and mortality rates that seem to be improving. In patients 
with end-stage liver disease and Budd-Chiari it is the 
treatment of choice. Further long-term follow-up of pa-
tients with shunt surgery for Budd-Chiari, as well as with 
transplantation for Budd-Chiari, will be needed to deter-
mine the best treatment for patients with the Budd-Chiari 
syndrome and intermediate degrees of liver failure. 
References 
I. Mitchell MC, Boitnoff JK, Kaufman S, et al. Budd-Chiari Syndrome: 
etiology, diagnosis and management. Medicine 1982; 61:199-
218. 
2. Ualla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis 
in relation to recent use of oral contraceptives. Gastroenterology 
1986; 90:807-811. 
3. Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-
Chiari syndrome. Surgery 1985; 97:242-245. 
4. Valla D, Casa deuvall N, Lacombe C, et al. Primary myeloprolif-
erative disorders and hepatic vein thrombosis. Ann Internal Med 
1985; 103:329-334. 
5. Disney TE, Sullivan SN, Haddad RG, et al. Budd-Chiari syndrome 
with inferior vena cava obstruction associated with systemic lupus 
erythematosus. J Clin Gastroentero1 1984; 6:253-256. 
6. Seltman JH, Dekker A, Van Thiel DH, et al. Budd-Chiari syndrome 
recurring in a transplanted liver. Gastroenterology 1983; 84:640-
643. 
7. Campbell DA, Rolles, K, Tamieson N, et al. Hepatic transplantation 
with perioperative and long term anti-coagulation as treatment 
for the Budd-Chiari syndrome. Surg Gynecol Obstet 1988; 166: 
511-518. 
8. Starzl TE, Porter KA, Putnam CW, et al. Orthotopic liver trans-
plantation in ninety-three patients. Surg Gynecol Obstet 1976; 
142:487-505. 
9. Starz1 TE, Iwatsuki S, Esquivel CO, et al. Refinements in the surgical 
technique ofliver transplantation. Semin Liver Dis 1985; 5:349-
356. 
10. Putnam CW, Porter KA, Weil R III, et al. Liver transplantation for 
Budd-Chiari syndrome. JAMA 1976; 236:1142-1143. 
11. Parker RGF. Occlusion of the hepatic veins in man. Medicine 1959; 
38:369-402. 
12. Tavill AS, Wood EJ, Kreel L, et al. The Budd-Chiari syndrome: 
correlation between hepatic scintigraphy and the clinical, radio-
logical and pathological findings in 19 cases of hepatic venous 
outflow obstruction. Gastroenterology 1975; 68:509-518. 
13. Warren RL, Sehlant RC, Wenjer NK, Galambos JT. Treatment of 
Budd-Chiari syndrome with streptokinase. Gastroentero1 1972; 
62:200. 
14. Greenwood LH, Yrizarry JM, Hallett JW, Seoville GS. Urokinase 
treatment of the Budd-Chiari syndrome. AJR 1983; 141:1057-
1059. 
15. Malt RA, Dalton JC, Johnson RE, Gurewich V. Side-to-side por-
tacaval shunt versus nonsurgical treatment of Budd-Chiari syn-
drome. Am J Surg 1978; 136:387-389. 
16. Powell-Jackson PR, Melia W, Canalese J, et al. Budd-Chiari syn-
drome: Clinical patterns and therapy. Quarterly J Med 1982; 
201:79-88. 
17. McDermott WV, Stone MD, Bothe A, Trey C. Budd-Chiari syn-
drome: historical and clinical review with an analysis of surgical 
corrective procedures. Am J Surg 1984; 147:463-467. 
18. Millikan WJ, Henderson JM, Sewell CW, et al. Approach to the 
spectrum ofBudd-Chiari syndrome: which patients require portal 
decompression? Am J Surg 1985; 149:167-176. 
19. Cameron JL, Herlong HF, Sanfey H, et al. The Budd-Chiari syn-
drome. Ann Surg 1983; 198:335-336. 
20. McCarthy PM, Van Heerden JA, Adson MA, et al. The Budd-Chiari 
syndrome. Arch Surg 1985; 120:657-662. 
21. Ahn SS, Yellin A, Sheqj FC, et al. Selective surgical therapy of the 
Budd-Chiari syndrome provides superior survivor rates than 
conservative medical management. J Vase Surg 1987; 5:28-37. 
22. Hirooka M, Kimnra C. Membranous obstruction of the hepatic 
portion of the inferior vena cava. Arch Surg 1970; 100:656-663. 
23. Pezzuoli G, Spina GP, Opocher E, et al. Portacaval shunt in the 
treatment of primary Budd-Chiari syndrome. Surgery 1985; 98: 
319-323. 
24. Vons C, Smadja C, Bourstyn E, et al. Results of portal systemic 
shunts in Budd-Chiari syndrome. Ann Surg 1986; 203:366-370. 
25. Orloff MJ, Johansen KH. Treatment of Budd-Chiari syndrome by 
side-to-side portacaval shunt: experimental and clinical results. 
Ann Surg 1978; 188:494-512. 
26. Orloff MJ, Girard B. Treatment of Budd-Chiari syndrome by side-
to-side portacaval shunt: long term results. Hepatology 1986; 6: 
1181. 
27. Casella JF, Bontempo FA, Markel H, et al. Successful treatment of 
homozygous protein C deficiency by hepatic transplantation. 
Lancet 1988; i:435-437. 
